OWD
DNLI icon

Osborn Williams & Donohoe’s Denali Therapeutics DNLI Stock Holding History

Osborn Williams & Donohoe’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-14,000
Closed -$214K – 305
2019
Q3 		$214K Hold
14,000
– – 0.02% 299
2019
Q2 		$291K Hold
14,000
– – 0.03% 276
2019
Q1 		$386K Buy
14,000
+4,000
+40% +$83.7K 0.04% 276
2018
Q4 		$207K Hold
10,000
– – 0.04% 209
2018
Q3 		$217K Buy
+10,000
New +$165K 0.03% 217

Other funds holding DNLI

CM
Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Osborn Williams & Donohoe's DNLI Position: Q4 2019 in Review

Osborn Williams & Donohoe sold out of Denali Therapeutics (DNLI) in Q4 2019, closing a stake of 14,000 shares — an estimated $214K sold.

Osborn Williams & Donohoe first reported a position in DNLI in Q3 2018 and held it in 5 quarters. The position peaked at $386K in Q1 2019. 108 funds tracked by Wall St. Rank hold DNLI as of Q4 2019.

  • Osborn Williams & Donohoe reported no remaining Denali Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Osborn Williams & Donohoe sold 14,000 Denali Therapeutics shares in Q4 2019, an estimated $214K.
  • Osborn Williams & Donohoe first reported a position in Denali Therapeutics in Q3 2018 and held it in 5 quarters.
  • Osborn Williams & Donohoe's Denali Therapeutics position peaked at $386K in Q1 2019.
  • 108 funds tracked by Wall St. Rank held Denali Therapeutics as of Q4 2019.

Based on Osborn Williams & Donohoe's 13F filing for Q4 2019, filed 2 Mar 2020.